erlizumab

As nouns the difference between terms and erlizumab

is that terms is while erlizumab is a recombinant humanized monoclonal antibody developed to treat heart attack, stroke, and traumatic shock.

As nouns the difference between shock and erlizumab

is that shock is sudden, heavy impact or shock can be an arrangement of sheaves for drying, a stook while erlizumab is a recombinant humanized monoclonal antibody developed to treat heart attack, stroke, and traumatic shock.

As a verb shock

is to cause to be emotionally shocked or shock can be to collect, or make up, into a shock or shocks; to stook.

As an adjective traumatic

is traumatic.

As a noun erlizumab is

a recombinant humanized monoclonal antibody developed to treat heart attack, stroke, and traumatic shock.

As nouns the difference between stroke and erlizumab

is that stroke is an act of while erlizumab is a recombinant humanized monoclonal antibody developed to treat heart attack, stroke, and traumatic shock.

As a verb stroke

is to move one's hand or an object (such as a broom) along (a surface) in one direction.

As a verb humanized

is past tense of humanize.

As a noun erlizumab is

a recombinant humanized monoclonal antibody developed to treat heart attack, stroke, and traumatic shock.

As nouns the difference between recombinant and erlizumab

is that recombinant is an organism, cell or haplotype formed by genetic recombination while erlizumab is a recombinant humanized monoclonal antibody developed to treat heart attack, stroke, and traumatic shock.

As an adjective recombinant

is referring to something formed by combining existing elements in a new combination especially in the phrase recombinant dna referring to an organism created in the lab by adding dna from another species.